Botulinum toxin A versus bupivacaine trigger point injections for the treatment of myofascial pain syndrome: A randomised double blind crossover study

2007 ◽  
Vol 2007 ◽  
pp. 242
Author(s):  
S.E. Abram
Keyword(s):  
Botulinum Toxin ◽  
Crossover Study ◽  
Myofascial Pain ◽  
Trigger Point ◽  
Botulinum Toxin A ◽  
Pain Syndrome ◽  
Myofascial Pain Syndrome ◽  
Double Blind ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

scholarly journals COMPARATIVE PROSPECTIVE STUDY OF THE EFFECTIVENESS AND SAFETY OF RUSSIAN OF THE RUSSIAN BOTULINUM TOXIN-A RELATOX ® IN ORDER TO CORRECT THE OF MASTICATORY MUSCLES HYPERTONE PATIENTS WITH MYOFASCIAL PAIN SYNDROME

2019 ◽  
Vol 23 (3-4) ◽  
pp. 180-184
Author(s):  
Marina I. Soykher ◽  
O. R Orlova ◽  
L. R Mingazova ◽  
M. G Soykher ◽  
A. A Mammedov
Keyword(s):  
Botulinum Toxin ◽  
Myofascial Pain ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
Pain Syndrome ◽  
Myofascial Pain Syndrome ◽  
Botulinum Toxin Type ◽  
Masticatory Muscles ◽  
Toxin A ◽  
Safety And Efficacy

Treatment of diseases of the temporomandibular joint (TMJ), complicated by hypertension of the masticatory muscles, remains one of the unsolved problems of dentistry. The purpose of this clinical study is to assess the safety and efficacy of the first Russian botulinum toxin a (BTA) Relatox® for the correction of masticatory muscle hypertension in patients with myofascial pain syndrome, as well as its comparison with the Lantox® by these parameters. Injections of botulinum toxin type A are a method of treatment in patients with myofascial facial pain syndrome with high therapeutic potential. The analysis of clinical results of using the Russian botulinum toxin type A of Relatox® shows high clinical efficacy. Comparative analysis of Lantox® and Relatox® showed no differences in safety and efficacy.

Sign in / Sign up

Export Citation Format

Share Document